Introduction of direct-acting antivirals against hepatitis C virus (HCV) has provided a revolutionary improvement in the treatment outcome. In contrast to HCV, however, the strategy for developing new antiviral agents against hepatitis B virus (HBV), especially viral-targeting compounds, is limited because HBV requires only four viral genes for its efficient replication/infection. Here, we identify an oligomeric flavonoid, proanthocyanidin (PAC) and its analogs, which inhibit HBV entry into host cells by targeting the HBV large surface protein (LHBs). Through cell-based chemical screening, PAC was identified to inhibit HBV infection with little cytotoxic effect. PAC prevented the attachment of the preS1 region in the LHBs to its cellular receptor, sodium taurocholate cotransporting polypeptide (NTCP). PAC was shown to target HBV particles and impair their infectivity, whereas it did not affect the NTCP-mediated bile acid transport activity. Chemical biological techniques demonstrated that PAC directly interacted with the region essential for receptor binding in the preS1 region in the LHBs protein. Importantly, PAC had a pan-genotypic anti-HBV activity and was also effective against a clinically relevant nucleoside analog-resistant HBV isolate. We further showed that PAC augmented the ability of a nucleoside analog, tenofovir, to interrupt HBV spread over time in primary human hepatocytes by cotreatment. Moreover, derivative analysis could identify small molecules that demonstrated more-potent anti-HBV activity over PAC. Conclusion: PAC and its analogs represent a new class of anti-HBV agents that directly target the preS1 region of the HBV large surface protein. These agents could contribute to the development of a potent, well-tolerated, and broadly active inhibitor of HBV infection. (HEPATOLOGY 2017;65:1104-1116.
H epatitis B virus (HBV) causes a major public health problem, chronically infecting approximately 240 million people worldwide.
(1) HBV infection is associated with a wide spectrum of liver diseases, including chronic hepatitis, that can eventually lead to cirrhosis and hepatocellular carcinoma. (2, 3) The current anti-HBV treatment is mainly based on either nucleos(t)ide analogs (NAs) or interferons (IFNs). (2, 4, 5) Abbreviations: aa, amino acids; cccDNA, covalently closed circular DNA; CC 50 , half maximal cytotoxic concentration; HBc, hepatitis B core; HBe, hepatitis B e; HBIG, hepatitis B immunoglobulin; HBs, HBV surface protein; HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human immunodeficiency virus; IC 50 , half maximal inhibitory concentration; IFN, interferon; LHBs, large HBV surface protein; LT, liver transplantation; NA, nucleos(t)ide analog; NTCP, sodium taurocholate cotransporting polypeptide; OHBF-C, oolonghomobisflavan C; PCR, polymerase chain reaction; peg-IFN, pegylated interferon; PAC, proanthocyanidin; SPR, surface plasmon resonance; TCA, taurocholic acid; VSV, vesicular stomatitis virus.
NAs, such as lamivudine, adefovir, entecavir, tenofovir, and telbivudine, suppress HBV replication in host hepatocytes through targeting HBV polymerase to inhibit viral reverse transcription. IFNa and its pegylated form (peg-IFNa) exert antiviral effects by modulating the immune response or directly inhibiting viral replication in hepatocytes. These agents efficiently reduce the viral load in patients and lead to remission of hepatitis; however, their effectiveness in complete elimination of HBV from infected cells is limited. (4, 5) Moreover, long-term treatment with some of these NAs often results in the development of drug-resistant mutations, which decreases treatment efficacy. Additionally, IFNs can present serious adverse effects with low tolerability. In order to further improve anti-HBV treatment, the development of new anti-HBV agents is urgently needed.
Multidrug treatment generally provides great therapeutic benefit, as shown by the successful progress of antiviral treatments against human immunodeficiency virus (HIV) and hepatitis C virus (HCV). (6) (7) (8) These antiviral multidrug treatments use different classes of antiviral agents, thus development of inhibitors with different mode of action is greatly demanded for the improvement of HBV treatment. In contrast to HIV and HCV, HBV requires only four viral genes for its efficient replication/infection: core, polymerase, surface (HBs), and x proteins. (4, 5, 9) Clinically available NAs target the reverse-transcriptase activity of the polymerase protein. Additional HBV-targeting compounds reported in preclinical studies or under clinical development phases include a series of small molecules, such as a-hydroxytropolone derivatives, that inhibit the RNaseH activity of the polymerase protein, (10) and heteroaryldihydropyrimidines and phenylpropenamides that interact with the HBV core protein and abort functional capsidation. (11, 12) Hepatitis B immunoglobulin (HBIG) is a human-derived antibody that can neutralize infection, and it is clinically used to prevent vertical transmission at birth or transmission upon liver transplantation (LT) and as a postexposure prophylaxis. (13, 14) Identification of anti-HBV compounds that target different viral factors will offer an additional strategy for antiviral treatment. In this study, we identified HBV entry inhibitors that target the HBV envelope proteins with a unique mode of action.
HBV enters into host cells with following a multiple step process, which consist of a low affinity viral attachment to hepatocytes, and a subsequent highaffinity interaction with a specific receptor that can trigger viral internalization. (15) HBV particles contain three envelope proteins: small, middle, and large HBs (LHBs). Among these proteins, the LHBs, especially the amino terminal 2-48 amino acids (aa) of the preS1 region, plays an essential role in the entry process through binding to an entry receptor, sodium taurocholate cotransporting polypeptide (NTCP). (16) (17) (18) (19) (20) To date, selective HBV entry inhibitors have been identified, including myrcludex-B, bile acids, cyclosporins, ezetimibe, ritonavir, irbesartan, and vanitaracin A, all of which have been shown to directly target NTCP. (19, (21) (22) (23) (24) (25) (26) (27) (28) It was also found that all of these agents can impair the original function of NTCP, that is, sodium-dependent bile acid uptake into hepatocytes, through molecular interaction with NTCP. (29) (30) (31) Here, we identify plant-derived products, proanthocyanidin (PAC) and its analog, oolonghomobisflavanes, as entry inhibitors of HBV and hepatitis D virus (HDV). The use of chemical biological techniques demonstrated that PAC targeted HBV particles through direct interaction with the preS1 region of the LHBs. Importantly, PAC did not impair cellular sodium-dependent bile acid uptake, in contrast to most of the reported HBV entry inhibitors. This is likely to be a novel type of anti-HBV inhibitors with a unique mode of action.
Materials and Methods

STATISTICAL ANALYSIS
Statistical significance was determined using the Student t test (*P < 0.05; **P < 0.01).
Other experimental procedures are shown in the Supporting Information.
Results
PAC INHIBITS HBV INFECTION
We have previously established the HepG2-hNTCP-C4 cell line, a highly HBV-susceptible cell line expressing the human NTCP gene in HepG2 cells. (21) Using this cell line, we screened for small molecules that inhibit HBV infection by following the methods previously reported for identification of HBV entry inhibitors (27) : HepG2-hNTCP-C4 cells were pretreated with compounds for 24 hours and were then inoculated with HBV in the presence of compounds for 16 hours. After washing out free HBV and compounds, and culturing the cells for a further 12 days, HBV infection was evaluated by quantifying the HBs antigen secreted from the infected cells (Fig. 1A) . PreS1 peptide, a lipopeptide consisting of 2-48 aa of the preS1 region of the HBV large surface protein (LHBs), which is a known HBV entry inhibitor, significantly reduced the HBs level in this screening (Fig.  1B) . Among the tested compounds, PAC [CAS No. 18206-61-6] (32, 33) was the most efficient in reducing the HBs level (Fig. 1B, left) without exerting any cytotoxicity (Fig. 1B, right) . Similar to the effect of the preS1 peptide, treatment with PAC at 20 lM also significantly reduced hepatitis B e (HBe) antigen in the culture supernatant (Fig. 1C) . Intracellular hepatitis B core (HBc) antigen (Fig. 1D ), HBV DNA (Fig. 1E) , and covalently closed circular DNA (cccDNA; Fig.  1F ) were all consistently decreased by treatment with PAC. This effect was not limited to infection of HepG2-hNTCP-C4 cells, given that similar anti-HBV effect of PAC was observed in more physiologically relevant cell-culture models, HepaRG cells ( Fig.   2A ) and primary human hepatocytes (Fig. 2B ). These data suggest that PAC inhibits HBV infection.
PAC BLOCKS HBV ATTACHMENT TO NTCP
PAC decreased HBV infection in a dose-dependent manner (Fig. 3A, left) , as monitored by the level of HBs antigen secreted from infected primary human hepatocytes without showing significant cytotoxicity (Fig. 3A [right] and Supporting Fig. S1 ). The half maximal inhibitory concentration (IC 50 ) and cytotoxic concentration (CC 50 ) were calculated as approximately 7.860.75 and >80 lM, respectively. In an HBV infection assay with long-term treatment (39 days), PAC at a concentration as low as 3 lM clearly showed an anti-HBV activity in primary human hepatocytes without cell toxicity.
We next investigated which step in the HBV life cycle was blocked by PAC. The HBV life cycle can be generally divided into two phases: (1) the early phase that includes attachment/entry, trafficking to the nucleus, and cccDNA formation and (2) the replication phase consisting of the steps including transcription, encapsidation, reverse transcription, envelopment, and release. (4, 9, 27) We examined the effect of PAC on the replication phase using Hep38.7-Tet cells, which support HBV replication under depletion of tetracycline, but do not mediate the early phase of infection. (34) HBV replication was induced by depletion of tetracycline in the presence or absence of compounds for 6 days, and then HBV DNA in the cells was quantified by real-time polymerase chain reaction (PCR). Although lamivudine and entecavir, clinically used reverse-transcriptase inhibitors, (4, 5) drastically decreased HBV DNA, PAC at 20 lM had no significant effect on HBV DNA (Fig. 3B) . A time of addition assay shown in Fig. 3C indicated that PAC reduced HBV infection when it was added during HBV inoculation ( Fig. 3C -a,C-b), whereas PAC treatment after viral infection did not show any anti-HBV effect, similar to preS1 peptide, a known inhibitor of the attachment/entry process ( Fig. 3C-c) . Thus, PAC is likely to block the entry phase.
We further examined whether PAC interfered with viral attachment to the host cell surface by using a previously described HBV attachment assay in which HepG2-hNTCP-C4 cells were incubated with HBV at 48C, which allows viral attachment, but not subsequent internalization. (35) Cells preincubated with compounds for 2 hours were exposed to HBV in the presence of the compounds for 3 hours at 48C, and HBV attached to the cell surface was quantified by measuring HBV DNA. PAC, as well as preS1 peptide, significantly reduced cell-associated HBV DNA, whereas lamivudine did not (Fig. 3D ). Consistently, cell binding of preS1 peptide (2-48 aa), which is critically involved in specific HBV attachment to host cells, (16) (17) (18) was drastically inhibited following treatment with either 20 lM of PAC or the nonlabeled preS1 peptide. In contrast, 80 lM of procyanidin B1 (CAS No. 20315-25-7), an analog of PAC, could not prevent the preS1 cell binding (Fig. 3E ) and could not inhibit HBV infection (Supporting Fig. S2 ).
The preS1 region (2-48 aa) of the LHBs interacts with its cellular binding partner, NTCP, to mediate viral entry. (20) We then developed the binding assay between the preS1 (2-48 aa) and NTCP in vitro as described in Materials and Methods. In this pull-down assay, recombinant His-tagged NTCP coprecipitated with a biotinylated preS1 peptide (Fig. 3F , upper, lane 4), but not with a biotinylated-HCV E1 peptide (111-140 aa), a nonrelevant control peptide, and not with agarose beads itself (Fig. 3F , upper, lanes 2 and 3). Mutations in 9-16 aa of the preS1 peptide markedly reduced the binding affinity to recombinant His-NTCP (Fig. 3F) , further demonstrating that NTCPpreS1 interaction in this in vitro binding assay is specific. In this assay, treatment with PAC remarkably prevented the preS1-NTCP interaction, whereas procyanidin B1 did not inhibit this interaction (Fig. 3F , upper, lanes 5 and 6). These data indicate that PAC specifically blocks the preS1-NTCP interaction to reduce HBV attachment to host cells.
PAC TARGETS HBV PARTICLES TO REDUCE THE VIRAL INFECTION
We then examined whether PAC targeted host cells or HBV particles to inhibit HBV infection. To determine whether PAC targeted host cells, we first prepared "compound-pretreated cells" by pretreating HepG2-hNTCP-C4 cells with compounds for 24 hours. After washing out free compounds, susceptibility of cells to HBV was examined in the absence of compounds (Fig.  4A) . HBV infection was reduced in HepG2-hNTCP-C4 cells after treatment with preS1 peptide, a hosttargeting entry inhibitor, but this was not the case with PAC nor heparin, which binds to HBV particles (Fig.  4A) . (36) To determine whether PAC targeted HBV, we prepared "compound-pretreated HBV particles" by treating HBV with compounds for 30 minutes before inoculation. After washing out free compound by ultrafiltration, the infectivity of these "compound-pretreated HBV particles" was analyzed in the HBV infection assay in the absence of compounds (Fig. 4B) . PAC-pretreated HBV showed a drastic reduction in infectivity, as did heparinpretreated particle, but not preS1 peptide-pretreated HBV (Fig. 4B) . These data suggest that PAC targets HBV particles, rather than host cells, to inhibit viral infection. This notion was further supported by an NTCP transporter assay. A series of anti-HBV entry inhibitors, including preS1 peptide, cyclosporin A, irbesartan, ezetimibe, ritonavir, and vanitaracin A, were shown to target NTCP and could inhibit its function of sodium-dependent bile acid uptake into hepatocytes. (19, (21) (22) (23) (24) (25) (26) (27) (28) We therefore measured the uptake of [ 3 H]-taurocholic acid (TCA) by HepG2-hNTCP-C4 cells in the presence or absence of compounds under either sodium-free or -containing conditions. Although preS1 peptide drastically impaired sodium-dependent TCA uptake, PAC at 20 lM had little effect on the bile acid uptake mediated by NTCP (Fig. 4C) . These results suggest that PAC targets HBV particles to inhibit the infection without dysregulating NTCP transporter activity.
PAC DIRECTLY INTERACTED WITH THE 2-48 aa REGION OF THE preS1
We further analyzed the interaction between PAC and HBV particles. For a pull-down assay, PAC, and procyanidin B1 as a negative control, were crosslinked with a biotin-linker carrying a diazirine moiety by a photoaffinity labeling method. (37) HBV particles were incubated with the biotinylated PAC or procyanidin B1 that were immobilized on streptavidin-agarose beads, and HBV coprecipitated with the compoundimmobilized beads was detected with an antibody against the preS1 region. HBV particles selectively coprecipitated with PAC-immobilized beads (Fig. 5A,  lane 3 ), but not with nonimmobilized or procyanidin B1-beads (Fig. 5A, lanes 2 and 5) . This binding between PAC and HBV particles was competed out by adding excess amounts of free PAC (Fig. 5A, lane 4) , indicating that HBV specifically interacted with PAC. As a control, a nonrelevant protein, albumin, was not bound to any of these beads (Fig. 5A, lower panel) . Given that PAC could inhibit the molecular interaction between preS1 (2-48 aa) and NTCP (Fig. 3F) , we reasoned that PAC might interact with the 2-48 aa region of the preS1. In a surface plasmon resonance (SPR) analysis, biotinylated peptide consisting of the preS1 (2-48 aa) or HCV E1 (111-140 aa), used as a negative control, were immobilized on SA sensor chips, and then different concentrations of PAC or procyanidin B1 were injected for 120 seconds. Injection of PAC over the preS1 peptide-immobilized chip yielded a dose- dependent SPR response (Fig. 5B-a) , whereas such responses were not produced by procyanidin B1 injection (Fig. 5B-b) . PAC did not show robust binding responses to the HCV E1 peptide (Fig. 5B-c) . These results clearly demonstrate that PAC directly binds to HBV particles through the 2-48 aa region of the preS1 of the LHBs. In further in vitro binding assays, the region 2-21 aa, but not 17-36 aa nor 29-47 aa of the preS1 region, showed an SPR signal response on immobilized biotinylated PAC (Supporting Fig. S3 ). Introduction of mutations at 9-16 aa (from NPLGFFPD to AAAAAAAA) within 2-21 aa of the preS1 peptide drastically reduced the SPR signal on immobilized biotinylated PAC (Supporting Fig. S3) , consistent with the involvement of 9-16 aa of the preS1 region in PAC interaction. 
IDENTIFICATION OF PAC ANALOGS WITH HIGHER Anti-HBV POTENCIES
We then performed a derivative analysis to identify small molecules with higher anti-HBV potencies than PAC. Because PAC contained flavanol moieties, we used seven compounds having flavanol moieties or flavonoids as PAC analogs (Supporting Fig. S4A ). Among these compounds, oolonghomobisflavan C (OHBF-C; CAS NO. 126716-06-1) (38) (Fig. 6A ) had the strongest activity to inhibit HBV infection (Fig.  6B,C and Supporting Fig. S4B ). OHBF-C inhibited the attachment of a fluorescence-labeled preS1 peptide to host cells and also reduced HBV infection at lower concentrations compared with PAC (Fig. 6B,C) . Its anti-HBV activity was IC 50 : 4.361.2 lM. Similar to PAC, OHBF-C did not affect HBV replication activity, as monitored by Southern blotting analysis using Hep38.7-Tet cells (Fig. 6D ), but it did reduce the infectivity of HBV by pretreatment of HBV particles (Fig. 6E) .
PAC SHOWS AN Anti-HBV EFFECT AGAINST MULTIPLE GENOTYPES AND AN ENTECAVIR-RESISTANT HBV ISOLATE
All the data described above were obtained by using an HBV genotype D. We then examined the effect of PAC on different HBV genotypes in primary human hepatocytes. The anti-HBV activity of PAC was conserved for all of the HBV genotypes tested (genotype A, B, C, and D; Fig. 7A ). More important, PAC was also effective against infection of a clinically relevant entecavir-resistant HBV isolate that carries mutations in L180M, S202G, and M204V, to a similar extent as against the corresponding wild-type genotype C (Fig. 7A) .
Additionally, we examined the effect of PAC on the infection of other viruses, HDV and vesicular stomatitis virus (VSV). Given that HDV possesses the same envelope as HBV, it is assumed that both viruses follow similar, or even identical, mechanisms, at least for the early entry process. As expected, treatment with PAC at 20 lM inhibited HDV infection, but it did not affect VSV envelope-mediated infection that uses a different entry process (Fig. 7B and Supporting  Fig. S5 ).
COTREATMENT EFFECT OF PAC WITH TENOFOVIR ON THE SPREAD OF HBV INFECTION
We further investigated the effect of cotreatment of PAC with tenofovir on the spread of HBV infection. We have reported that HBV infection of freshly isolated primary human hepatocytes can spread during long-term culture through production of infectious virions from infected cells and reinfection into na€ ıve cells. (39) The number of HBV-positive cells as well as the amount of HBV DNA in the culture supernatant were increased for up to 39 days after inoculation in the absence of a compound, consistent with the previous article reporting that HBV infection expanded rapidly, especially after 22 days postinfection (39) (Fig. 7C , PreS1-NTCP pull-down assay. Biotinylated preS1 peptide (2-48 aa), HCV E1 peptide (111-140 aa), or preS1 carrying the mutation at 9-16 aa (PLGFFPDH to AAAAAAAA) immobilized on streptavidin-agarose beads was incubated with recombinant His-tagged NTCP protein in the presence or absence of PAC or procyanidin B1 as an inactive control compound. Anti-His antibody was used to detect beads-bound NTCP protein by immunoblot. Abbreviations: DAPI, 4 0 ,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide; OD 450 , optical density at 450 nm. panels a-e, 7D, black, and Supporting Fig. S6A,  black) . However, such spread of infection, and the production of HBV, were reduced by continuous treatment with 3 lM of PAC or 1 nM of tenofovir (Fig.  7C, panels f-o and D, cyan and blue) . Notably, cotreatment with 3 lM of PAC and 1 nM of tenofovir further inhibited viral spread and production of HBV, without showing any cytotoxic effect (Fig. 7C , panels p-t, and D, red). Intracellular cccDNA levels were also significantly reduced by cotreatment with PAC and tenofovir (Supporting Fig. S6B ). Note that the 3-lM concentration, corresponding to 1.8 lg/mL, which is the concentration of PAC used in this experiment is clinically relevant, as the serum concentration of PAC reaches a concentration of 10 lg/mL of after oral intake of grape seed extract, a dietary supplement, in humans. (32, 33) Importantly, we also showed that posttreatment of PAC from 48 hours after HBV inoculation, as well as treatment together with or previous inoculation, were effective on significantly interrupting HBV spread over time in primary human hepatocytes (Supporting Fig. S7 ). Our data show the advantage of multidrug treatment, whereby cotreatment of an HBV entry inhibitor with a nucleoside analog could effectively enhance the anti-HBV potential of drugs.
Discussion
In this study, through a cell-based chemical screening, we identified PAC and its analogs as small molecules that inhibit the HBV/HDV entry process. These are likely to constitute a new class of anti-HBV compounds that directly target the 2-48 aa of the preS1 region in LHBs, which is the most essential element for molecular interaction with its receptor, NTCP. (20) Although further in-depth analysis is needed to precisely identify the residue(s) of the preS1 that is responsible for NTCP interaction, our results ( Fig. 5 and Supporting Fig. S3 ) are consistent with the involvement of 9-16 aa of the preS1 region in the interaction with PAC.
Given that the viral entry process is essential for initiating and expanding the infection, viral entry presents an attractive target for antiviral therapy. (15, 19) Clinical value of HBV entry inhibitors is firmly established based on their ability to prevent vertical transmission, as well as HBV recurrence post-LT. (13, 15) They are also useful as a postexposure prophylaxis. Hepatitis B immunoglobulin (HBIG) is the only clinically approved agent for HBV entry inhibition, but its high cost and intravenous administration present further medical needs for alternative drug development, presumably with different modes of action. (13, 14, 40) So far, compounds that selectively inhibit HBV entry were revealed to either (1) interact with NTCP, including, bile acids, myrcludex-B, cyclosporin A and its derivatives, irbesartan, ezetimibe, ritonavir, and vanitaracin A, (19, (21) (22) (23) (24) (25) (26) (27) (28) or (2) gallate, and Ro41-5253. (35, 41, 42) All these agents could impair bile acid uptake into hepatocytes by inhibiting NTCP transporter activity, and this raises a concern regarding the possibility of considerable adverse effects, although myrcludex-B, which is under clinical development, may have some window of concentration ranges that inhibit HBV infection, but minimally affect the transporter activity of NTCP.
PAC is a natural product mainly consisting of multimeric flavanol. (32, 33) The analog analysis ( Fig. 6 and Supporting Fig. S4) indicates that flavanol moiety itself is not sufficient for the anti-HBV activity (EGC had little anti-HBV activity), but oligomerized flavanol can possess an anti-HBV activity (OHBF-C had a strong anti-HBV activity). Further derivative analysis is needed to determine the chemical structure that is responsible for anti-HBV activity, which is to be analyzed in a future subject. PAC and OHBF-C are multimeric flavanol originally derived from grape seed and traditional Chinese tea, respectively, and have preferable safety profiles. (32, 33, 38) The serum PAC level was reported to reach 10 lg/mL after oral intake of 200 mg/day of grape seed extract in humans with no side effects, (33) and this concentration is expected to exert robust anti-HBV activity upon either single treatment or cotreatment with tenofovir ( Fig. 7) , based on our results. The anti-HBV activity of PAC in in vivo settings is the subject of future study. Treatment with HBIG during and after LT reduced HBV recurrence, and HBIG in combination with a nucleos(t)ide analog prevents the HBV recurrence rate to less than 10% in 1-2 years after transplantation. (43) As well, HBIG is used for prevention of vertical transmission. (44) New HBV entry inhibitors such as PAC might be used as alternatives to HBIG. Based on the results that HBV entry inhibition can reduce the intrahepatic cccDNA pool, entry inhibitors are likely to be effective on preventing de novo infection that occurred in clinical situations such as vertical transmission and HBV recurrence post-LT. Importantly, we further demonstrated the advantage of cotreatment of PAC and tenofovir that led to increased anti-HBV activity. These findings strongly encourage further analysis of PAC derivatives for the development of a novel class of anti-HBV agents. In contrast to HCV or HIV, which generate around 10 viral proteins, including multiple enzymes, HBV replication/infection is driven by only four genes and hence presents a limited number of drug targets. Our results shed a light on a strategy for developing new types of direct-acting antiviral agents that target nonenzymatic viral factors.
